Literature DB >> 16822383

Ocular allergy in pediatric practice.

Mark B Abelson1, David Granet.   

Abstract

Allergies occur frequently in all pediatric age groups, affecting up to 40% of children. Allergic conjunctivitis is the most common ocular allergy syndrome among children, with atopic keratoconjunctivitis and vernal keratoconjunctivitis comprising less common, but potentially more severe, forms of ocular allergy. In this article, we review the impact, diagnosis, potential complications, and treatment of these ocular allergic pediatric conditions. Early detection is necessary to prevent potentially serious consequences of pediatric ocular allergy. Involvement of pediatric ophthalmologists may be necessary to avoid preventable vision loss in severe cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822383     DOI: 10.1007/s11882-006-0064-x

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  41 in total

1.  A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.

Authors:  Constance H Katelaris; Giorgio Ciprandi; Luc Missotten; F Darell Turner; Donata Bertin; Gilles Berdeaux
Journal:  Clin Ther       Date:  2002-10       Impact factor: 3.393

2.  Topical cyclosporine in the management of shield ulcers.

Authors:  Altug Cetinkaya; Yonca Aydin Akova; Dilek Dursun; Aysel Pelit
Journal:  Cornea       Date:  2004-03       Impact factor: 2.651

Review 3.  Mast cell heterogeneity.

Authors:  A M Irani; L B Schwartz
Journal:  Clin Exp Allergy       Date:  1989-03       Impact factor: 5.018

4.  Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.

Authors:  J M Yanni; S T Miller; D A Gamache; J M Spellman; S Xu; N A Sharif
Journal:  Ann Allergy Asthma Immunol       Date:  1997-12       Impact factor: 6.347

5.  An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride.

Authors:  George W Ousler; Katrina A Wilcox; Gaurav Gupta; Mark B Abelson
Journal:  Ann Allergy Asthma Immunol       Date:  2004-11       Impact factor: 6.347

6.  A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.

Authors:  G J Berdy; D L Spangler; G Bensch; S S Berdy; R C Brusatti
Journal:  Clin Ther       Date:  2000-07       Impact factor: 3.393

7.  Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.

Authors:  N A Sharif; S X Xu; S T Miller; D A Gamache; J M Yanni
Journal:  J Pharmacol Exp Ther       Date:  1996-09       Impact factor: 4.030

8.  Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children.

Authors:  A Sabbah; M Marzetto
Journal:  Curr Med Res Opin       Date:  1998       Impact factor: 2.580

9.  Protective effect of loratadine on late phase reaction induced by conjunctival provocation test.

Authors:  G Ciprandi; S Buscaglia; E Marchesi; M Danzig; F Cuss; G W Canonica
Journal:  Int Arch Allergy Immunol       Date:  1993       Impact factor: 2.749

Review 10.  Prostaglandins and inflammatory reactions in the eye.

Authors:  P Bhattacherjee
Journal:  Methods Find Exp Clin Pharmacol       Date:  1980-02
View more
  2 in total

Review 1.  Pediatric keratoconus - Current perspectives and clinical challenges.

Authors:  Venugopal Anitha; Murugesan Vanathi; Anita Raghavan; Revathi Rajaraman; Meenakshi Ravindran; Radhika Tandon
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 2.  Allergic conjunctivitis: a comprehensive review of the literature.

Authors:  Mario La Rosa; Elena Lionetti; Michele Reibaldi; Andrea Russo; Antonio Longo; Salvatore Leonardi; Stefania Tomarchio; Teresio Avitabile; Alfredo Reibaldi
Journal:  Ital J Pediatr       Date:  2013-03-14       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.